HLA antigens and lymphocytes in proliferative vitreoretinopathy

Proença, Rui; Carvalho, Madalena; Proença, D; Veríssimo, Júlia; Regadas, Isaura; Travassos, Antônio Eustáquio Resende

doi:10.1007/bf00176434

Cited by 11 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immune responses following vitrectomy were not, however, limited to retina-intrinsic reactions. In accordance, previous studies have shown increased gliosis (GFAP-labeling) as well as increased presence of cellular antigens such as CD45 and CD68 in samples from patients with proliferative vitreoretinopathy (PVR) [45]. To explore the cellular involvement, we investigated three CD antigens with various roles in inflammation pathology.…”

Section: Discussionsupporting

confidence: 64%

Inflammatory responses after vitrectomy with vitreous substitutes in a rabbit model

Barth

Crafoord

Arnér

et al. 2019

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose To investigate the inflammatory response of current and future potential vitreous substitutes in an experimental in vivo vitrectomy model. Methods Twenty-five gauge pars plana vitrectomy was performed in the right eye of 60 pigmented rabbits, with subsequent injection of 0.5-1.0 ml of Healaflow® (cross-linked hyaluronic acid, n = 12), Bio-Alcamid® (polyalkylimide, n = 8), silicone oil (n = 12), or balanced saline solution (BSS, n = 28). Postoperative clinical evaluation was performed; and the rabbits were sacrificed at 1 day, 1 week, or 1 month. The eyecups were then examined macroscopically; the retinas sectioned and stained with hematoxylin and eosin (Htx), and immunohistochemically labeled for glial fibrillary acidic protein (GFAP), CD45, galectin-3, CD68, and CD20. Unoperated left eyes from treated animals as well as eyes from untreated animals were used as controls. Results Vitrectomy without major complications was achieved in 46/60 eyes. The remaining 14 eyes were analyzed separately. One eye developed endophthalmitis after 1 week and was excluded. Eyes treated with Healaflow®, silicone oil, and BSS had a comparable appearance macroscopically and in Htx-stained sections, whereas Bio-Alcamid®-injected eyes exhibited increased macroscopic inflammation and severely affected retinas. GFAP upregulation was present in all treatment groups, most prominent in eyes treated with Bio-Alcamid® and silicone oil. Upregulation of CD45 and CD68 in the inner retina and vitreous space was most prominent with Bio-Alcamid® treatment, and these eyes together with their silicone oil-treated counterparts also displayed a stronger upregulation of CD20-labeled cells compared with remaining groups. General upregulation of galectin-3, mainly in the inner retina, was found in all groups. In eyes with perioperative complications, labeling of CD45, CD68, and especially GFAP was comparably high. Conclusions We here describe differences in the postsurgery inflammatory profiles of existing and potential vitreous substitutes. Bio-Alcamid® and silicone oil display severe signs of gliosis and inflammation, whereas Healaflow® elicits minimal reactions comparable with BSS, highlighting its potential application as a vitreous substitute in a future clinical setting.

show abstract

Section: Discussionsupporting

confidence: 64%

Inflammatory responses after vitrectomy with vitreous substitutes in a rabbit model

Barth

Crafoord

Arnér

et al. 2019

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…These findings are concordant with those of Ricker et al which reported that both CXCL10 and CCL11 levels were higher in patients who developed postoperative PVR [10]. In addition, several immunohistochemical studies have demonstrated the presence of macrophages and lymphocytes in PVR membranes, further confirming the crucial role of inflammation in the PVR process [19][20][21][22]41].…”

Section: Discussionsupporting

confidence: 91%

Vitreous cytokine expression profiles in patients with retinal detachment

Conart¹,

Augustin²,

Rémen³

et al. 2021

Journal Français d'Ophtalmologie

View full text Add to dashboard Cite

“…3,4 Multiple lines of evidence support an immunologic model for the development of PVR. Immune cells have been demonstrated in PVR specimens, [5][6][7][8] and several studies have demonstrated a role for inflammatory cell signaling molecules in the development of PVR. 1,2,[9][10][11] Banerjee et al 12 compared vitreous cytokine levels among patients with a variety of retinal conditions and demonstrated a complex pattern of mediator concentrations in patients with PVR.…”

mentioning

confidence: 98%